Payment overview · 2025
General Payments
$86.53
4 reported records · 4 companies
Healthcare provider profile · identity verified
Holly Overmiller, DO
Allopathic & Osteopathic Physicians|Family Medicine · CALDWELL, OH · NPI 1407217995
Verified facts
What the public records show
CMS Open Payments records show Holly Overmiller, DO received $86.53 in general payments during 2025 across 4 reported records.
Exact Sciences Corporation accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.38 | 39.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.80 | 20.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.23 | 19.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.12 | 19.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $86.53 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.38 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 362 | 97 |
| Lisinopril | Lisinopril | 354 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 63 |
| Metformin Hcl | Metformin Hcl | 219 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 57 |
| Furosemide | Furosemide | 187 | 56 |
| Omeprazole | Omeprazole | 183 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 44 |
| Potassium Chloride | Potassium Chloride | 159 | 34 |
| Losartan Potassium | Losartan Potassium | 145 | 43 |
| Simvastatin | Simvastatin | 142 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 37 |
| Gabapentin | Gabapentin | 116 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 33 |
| Alendronate Sodium | Alendronate Sodium | 98 | 21 |
| Farxiga | Dapagliflozin Propanediol | 90 | 20 |
| Eliquis | Apixaban | 87 | 19 |
| Famotidine | Famotidine | 87 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 21 |
| Chlorthalidone | Chlorthalidone | 82 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 26 |
| Carvedilol | Carvedilol | 75 | 20 |
| Jardiance | Empagliflozin | 75 | 14 |
| Meloxicam | Meloxicam | 75 | 23 |
| Sertraline Hcl | Sertraline Hcl | 75 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 21 |
| Trazodone Hcl | Trazodone Hcl | 70 | 22 |
| Buspirone Hcl | Buspirone Hcl | 69 | 18 |
| Montelukast Sodium | Montelukast Sodium | 67 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 17 |
| Clonidine Hcl | Clonidine Hcl | 55 | 11 |
| Glipizide Er | Glipizide | 55 | 13 |
| Lovastatin | Lovastatin | 55 | 12 |
| Metformin Hcl Er | Metformin Hcl | 55 | 11 |
| Allopurinol | Allopurinol | 54 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 19 |
| Ezetimibe | Ezetimibe | 53 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 45 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 14 |
| Synthroid | Levothyroxine Sodium | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | 11 |
| Warfarin Sodium | Warfarin Sodium | 44 | 11 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 14 |
| Fenofibrate | Fenofibrate | 41 | 11 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 12 |
| Glipizide | Glipizide | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | 11 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $86.53 · 4 records | Exact Sciences Corporation | ABRYSVO, COMIRNATY, CREON, Cologuard Collection Kit, FREESTYLE LIBRE 3, PREVNAR 20 | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error